Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States
Authors
Keywords
-
Journal
Circulation-Cardiovascular Quality and Outcomes
Volume 14, Issue 5, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-05-10
DOI
10.1161/circoutcomes.120.007521
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
- (2019) Alanna M. Chamberlain et al. Journal of the American Heart Association
- Association between physician characteristics and payments from industry in 2015–2017: observational study
- (2019) Kosuke Inoue et al. BMJ Open
- Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data
- (2018) Manvi Sharma et al. BMC HEALTH SERVICES RESEARCH
- Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
- (2018) Jalpa A. Doshi et al.
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
- (2018) Jalpa A. Doshi et al. Circulation-Cardiovascular Quality and Outcomes
- Industry Payments to Cardiologists
- (2018) Amarnath Annapureddy et al.
- Types and Distribution of Payments From Industry to Physicians in 2015
- (2017) Kathryn R. Tringale et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Academic Detailing
- (2017) Jerry Avorn JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association
- (2017) Jerome D. Cohen et al. Journal of Clinical Lipidology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
- (2017) Ann Marie Navar et al. JAMA Cardiology
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Physician Payments Sunshine Act — Two Years of the Open Payments Program
- (2016) Shantanu Agrawal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
- (2016) William Fleischman et al. BMJ-British Medical Journal
- Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
- (2016) William Fleischman et al. BMJ-British Medical Journal
- Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts
- (2016) James S. Yeh et al. JAMA Internal Medicine
- Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries
- (2016) Colette DeJong et al. JAMA Internal Medicine
- Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
- (2015) Robert P. Giugliano et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Academic Detailing Can Play A Key Role In Assessing And Implementing Comparative Effectiveness Research Findings
- (2013) Michael A. Fischer et al. HEALTH AFFAIRS
- Physician adherence to the dyslipidemia guidelines is as challenging an issue as patient adherence
- (2011) G. Vashitz et al. FAMILY PRACTICE
- Fixed effects, random effects and GEE: What are the differences?
- (2008) Joseph C. Gardiner et al. STATISTICS IN MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now